Table 3.
Comparisons of glycated albumin of pregnant women with and without adverse pregnancy outcomes
| Case N/total |
Control N/total |
Odds ratio | P-value | |
|---|---|---|---|---|
| Non-GDM group (n = 327) | ||||
| Preterm delivery | 0/5 | 4/322 | 0.00 | 1.00 |
| Postpartum hemorrhage | 0/14 | 4/313 | 0.00 | 1.00 |
| Preeclampsia | 0/16 | 4/311 | 0.00 | 1.00 |
| Hypertension | 0/69 | 4/258 | 0.00 | 0.58 |
| LGA | 0/12 | 4/310 | 0.00 | 1.00 |
| GDM group (n = 894) | ||||
| Preterm delivery | 13/63 | 212/831 | 0.76 | 0.40 |
| Postpartum hemorrhage | 37/160 | 118/734 | 1.57 | 0.03 |
| Preeclampsia | 10/60 | 215/834 | 0.58 | 0.12 |
| Hypertension | 9/45 | 180/849 | 0.93 | 0.85 |
| LGA | 31/114 | 181/717 | 1.11 | 0.66 |
case: patients with the specific adverse pregnancy outcome; control: patients without specific adverse pregnancy outcome. LGA: large for gestation age. N: the number of subjects with GlyA greater-than-upper-limit (13.09%). total: the total number of the subjects with (case) or without (control) specific adverse pregnancy outcome. Chi-square test was performed for P value calculation. For the LGA study, the subjects with preterm delivery were excluded